Elmalik K, Chowdhury M M, Capps S N J
St George's Healthcare NHS Trust, Tooting, London, UK.
J Pediatr Urol. 2008 Aug;4(4):275-9. doi: 10.1016/j.jpurol.2008.01.205. Epub 2008 Mar 7.
To examine whether routine ureteric stenting influences outcome of pyeloplasty for pelvi-ureteric junction obstruction (PUJO).
A 10-year review was conducted of 105 consecutive open Anderson-Hynes dismembered pyeloplasties performed for PUJO, covering two periods: (1) pyeloplasties performed without ureteric stents (1994-1998) and (2) pyeloplasties performed with ureteric stents (1999-2003). Outcomes (expressed as means+/-SEM) of unstented patients (UPs; n=47) and stented patients (SPs; n=58) were compared and results analysed using ANOVA and chi-square tests.
Fifty-five patients (53.9%) presented with antenatal hydronephrosis, whilst 47 (46.1%) presented postnatally (at mean age 88.4+/-7.1 months) with one or more of the following: pain (n=30, 63.8%), urinary tract infection (n=16; 34.0%), haematuria (n=3, 6.4%), abdominal mass (n=3, 6.4%), acute renal failure (n=2, 4.3%), incidental finding (n=4, 8.5%). Pyeloplasty was performed (at mean age 58.9+/-5.3 months) for one or more of the following: pain (n=40, 38.1%), haematuria (n=6, 5.7%), urinary tract infection (n=18, 17.1%), poor initial or deteriorating function (n=29, 27.6%), severe or deteriorating hydronephrosis (n=41, 39.0%), calculus (n=1, 0.95%). Recognised complications of surgery were significantly higher in UPs (5 of 47; 10.6%) than SPs (0 of 58); P=0.016. These were leakage (n=4, 8.5%) and obstruction by blood clot (n=1, 2.1%). Nine SPs (15.5%) developed stent-related complications, including stent migration (n=5, 8.6%), infection (n=3, 5.2%) and calculus (n=1, 1.7%). SPs had significantly shorter hospital stay (2.71+/-0.25 days) than UPs (4.30+/-0.38 days); P<0.01. Preoperative renal pelvis antero-posterior diameter in SPs (3.24+/-0.25 cm) and UPs (3.21+/-0.28 cm) was comparable (P=0.80). Following pyeloplasty, a significant improvement from these preoperative baselines occurred earlier in SPs (at 3.10+/-0.46 months) than UPs (at 15.71+/-3.05 months); P<0.01.
Stented pyeloplasty significantly reduces complications from surgery, particularly leakage, and results in shorter hospital stay and earlier resolution of hydronephrosis, but at the expense of stent-related complications which could be avoided in future by the use of external stents.
探讨常规输尿管支架置入术是否会影响肾盂输尿管连接部梗阻(PUJO)肾盂成形术的疗效。
对连续105例行开放性Anderson-Hynes离断性肾盂成形术治疗PUJO的患者进行了为期10年的回顾性研究,分为两个阶段:(1)未行输尿管支架置入的肾盂成形术(1994 - 1998年);(2)行输尿管支架置入的肾盂成形术(1999 - 2003年)。比较未置入支架患者(UPs;n = 47)和置入支架患者(SPs;n = 58)的疗效(以均值±标准误表示),并采用方差分析和卡方检验分析结果。
55例患者(53.9%)产前出现肾积水,47例(46.1%)产后出现(平均年龄88.4±7.1个月),伴有以下一种或多种症状:疼痛(n = 30,63.8%)、尿路感染(n = 16;34.0%)、血尿(n = 3,6.4%)、腹部肿块(n = 3,6.4%)、急性肾衰竭(n = 2,4.3%)、偶然发现(n = 4,8.5%)。肾盂成形术(平均年龄58.9±5.3个月)用于治疗以下一种或多种情况:疼痛(n = 40,38.1%)、血尿(n = 6,5.7%)、尿路感染(n = 18,17.1%)、初始功能差或功能恶化(n = 29,27.6%)、重度或进行性肾积水(n = 41,39.0%)、结石(n = 1,0.95%)。UPs手术公认的并发症(47例中有5例;10.6%)显著高于SPs(58例中0例);P = 0.016。这些并发症为漏尿(n = 4,8.5%)和血凝块梗阻(n = 1,2.1%)。9例SPs(15.5%)出现与支架相关的并发症,包括支架移位(n = 5,8.6%)、感染(n = 3,5.2%)和结石(n = 1,1.7%)。SPs的住院时间(2.71±0.25天)显著短于UPs(4.30±0.38天);P < 0.01。SPs(3.24±0.25 cm)和UPs(3.21±0.28 cm)术前肾盂前后径相当(P = 0.80)。肾盂成形术后,与术前基线相比,SPs(3.10±0.46个月)较UPs(15.71±3.05个月)更早出现显著改善;P < 0.01。
置入支架的肾盂成形术显著降低手术并发症,尤其是漏尿,缩短住院时间并使肾积水更早消退,但代价是出现与支架相关的并发症,未来使用外部支架可避免这些并发症。